Dashboard
Manage Tickers

PNT PENTAIR plc

NYSE pentair.com


$ 0.02 (0.16 %)    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 623.15 $ 0.00 (0 %)
DIA $ 470.55 $ 0.00 (0 %)
SPY $ 676.21 $ 0.00 (0 %)
TLT $ 89.76 $ 0.00 (0 %)
GLD $ 365.06 $ 0.00 (0 %)
$ 12.5
-- x --
-- x --
-- - --
$ 6.57 - $ 14.35
3,290,996
na
17.48B
$ 0.53
$ 26.29
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-21-2025 09-30-2025 10-Q
2 07-22-2025 06-30-2025 10-Q
3 04-22-2025 03-31-2025 10-Q
4 02-25-2025 12-31-2024 10-K
5 10-22-2024 09-30-2024 10-Q
6 07-23-2024 06-30-2024 10-Q
7 04-23-2024 03-31-2024 10-Q
8 02-20-2024 12-31-2023 10-K
9 10-24-2023 09-30-2023 10-Q
10 07-27-2023 06-30-2023 10-Q
11 04-27-2023 03-31-2023 10-Q
12 02-21-2023 12-31-2022 10-K
13 10-25-2022 09-30-2022 10-Q
14 07-26-2022 06-30-2022 10-Q
15 04-21-2022 03-31-2022 10-Q
16 02-22-2022 12-31-2021 10-K
17 10-26-2021 09-30-2021 10-Q
18 07-27-2021 06-30-2021 10-Q
19 04-22-2021 03-31-2021 10-Q
20 02-16-2021 12-31-2020 10-K
21 10-20-2020 09-30-2020 10-Q
22 07-23-2020 06-30-2020 10-Q
23 04-30-2020 03-31-2020 10-Q
24 02-25-2020 12-31-2019 10-K
25 10-23-2019 09-30-2019 10-Q
26 07-23-2019 06-30-2019 10-Q
27 04-23-2019 03-31-2019 10-Q
28 02-19-2019 12-31-2018 10-K
29 10-23-2018 09-30-2018 10-Q
30 07-25-2018 06-30-2018 10-Q
31 04-20-2018 03-31-2018 10-Q
32 02-27-2018 12-31-2017 10-K
33 10-24-2017 09-30-2017 10-Q
34 07-25-2017 06-30-2017 10-Q
35 04-25-2017 03-31-2017 10-Q
36 02-21-2017 12-31-2016 10-K
37 10-25-2016 09-30-2016 10-Q
38 07-28-2016 06-30-2016 10-Q
39 04-26-2016 03-31-2016 10-Q
40 02-26-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

recent-ma-bodes-well-for-targeted-cancer-therapy-player-fusion-pharmaceuticals-analyst-say-astrazeneca-is-favorably-positioned
Recent M&A Bodes Well For Targeted Cancer ...
12/27/2023 17:42:14

With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted...

brookline-capital-downgrades-point-biopharma-global-to-hold-lowers-price-target-to-125
Brookline Capital Downgrades POINT Biophar...
12/21/2023 10:47:21

Brookline Capital analyst Kemp Dolliver downgrades POINT Biopharma Global (NASDAQ:PNT) from Buy to Hold and lowers the price...

lantheus-downgraded-due-to-reliance-on-pnt2002-analyst-cites-comparable-profile-to-novartis-drug
Lantheus Downgraded Due To Reliance On PNT...
12/19/2023 19:52:51

Monday, Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Ph...

why-is-prostate-cancer-focused-lantheus-stock-trading-lower-today
Why is Prostate Cancer Focused Lantheus St...
12/18/2023 16:47:57

Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SP...

Core News & Articles
Lantheus and POINT Biopharma Announce Topl...
12/18/2023 12:31:51

Lantheus Holdings, Inc. (Lantheus) (NASDAQ:LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ:PNT) today announced statistic...

Core News & Articles
Eli Lilly Announced The Extension Of The E...
12/04/2023 11:47:58

top-5-health-care-stocks-that-may-collapse-in-november
Top 5 Health Care Stocks That May Collapse...
11/17/2023 13:33:05

As of Nov. 17, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as ...

Core News & Articles
Eli Lilly And Company Extends Tender Offer...
11/17/2023 11:48:31

Core News & Articles
Lilly Announces Receipt Of NRC Consent in ...
11/14/2023 21:35:33

recap-point-biopharma-global-q3-earnings
Recap: POINT Biopharma Global Q3 Earnings
11/13/2023 12:35:05

Core News & Articles
Lilly Reports Extension Of Tender Offer To...
11/08/2023 23:12:58

The tender offer, which was previously scheduled to expire at one minute past 11:59 p.m., Eastern time, on Nov. 9, 2023, has be...

bvf-partners-lp-reports-165-stake-in-point-biopharma-global-as-of-nov-2-bvf-partners-purchased-point-biopharma-global-shares-based-on-belief-that-such-shares-when-purchased-were-undervalued
BVF Partners L.P. Reports 16.5% Stake In P...
11/06/2023 18:54:22

-SEC filing

benzingas-top-ratings-upgrades-downgrades-for-october-24-2023
Benzinga's Top Ratings Upgrades, Downgrade...
10/24/2023 15:00:43

piper-sandler-downgrades-point-biopharma-global-to-neutral-announces-125-price-target
Piper Sandler Downgrades POINT Biopharma G...
10/24/2023 10:35:44

Piper Sandler analyst Edward Tenthoff downgrades POINT Biopharma Global (NASDAQ:PNT) from Overweight to Neutral and announce...

benzingas-top-ratings-upgrades-downgrades-for-october-6-2023
Benzinga's Top Ratings Upgrades, Downgrade...
10/06/2023 15:00:44

raymond-james-downgrades-point-biopharma-global-to-market-perform
Raymond James Downgrades POINT Biopharma G...
10/06/2023 09:06:56

Raymond James analyst Rahul Sarugaser downgrades POINT Biopharma Global (NASDAQ:PNT) from Outperform to Market Perform.

benzingas-top-ratings-upgrades-downgrades-for-october-4-2023
Benzinga's Top Ratings Upgrades, Downgrade...
10/04/2023 15:00:28

truist-securities-downgrades-point-biopharma-global-to-hold-lowers-price-target-to-125
Truist Securities Downgrades POINT Biophar...
10/04/2023 13:32:41

Truist Securities analyst Nicole Germino downgrades POINT Biopharma Global (NASDAQ:PNT) from Buy to Hold and lowers the pric...

jonestrading-downgrades-point-biopharma-global-to-hold
JonesTrading Downgrades POINT Biopharma Gl...
10/04/2023 11:13:58

JonesTrading analyst Justin Walsh downgrades POINT Biopharma Global (NASDAQ:PNT) from Buy to Hold.

crude-oil-moves-higher-point-biopharma-global-shares-jump
Crude Oil Moves Higher; POINT Biopharma Gl...
10/03/2023 18:36:39

U.S. stocks extended losses toward the end of trading, with the S&P 500 falling around 1.5% on Tuesday. The Dow traded dow...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION